Breast Cancer Start-up Challenge
Connect with Us
  • Winning Teams
  • Startups Launched
  • Phases
    • Start-up Phase
    • Eligibility & Rules
  • Resources
    • Inventions >
      • 1 Diagnostic from biopsies with software analysis
      • 2 Immunotherapy Using Modified Self Tumor Cells
      • 3 Combination of Tissue Reconstruction and Recurrence Prevention
      • 4 Human monoclonal Antibody Based Cancer Therapies
      • 5 Immunotherapy Using Granulysin Activated Monocytes
      • 6 Anti-cancer Toxin
      • 7 Versatile Delivery Method for Cancer Therapeutics
      • 8 Genomic Based Diagnostic Assay
      • 9 Tissue-based Diagnostic Assay
      • 10 Diagnostic Kit for Therapy Benefit Prediction
    • Seed Funders
  • Media
    • News and Past Events
  • Team Blogs
  • Teams
    • Teams Accepted
    • Core Team
    • Judges
    • Challenge Supporters
  • Contact Us

Welcome to Mesopharm Therapeutics

4/7/2014

1 Comment

 
Mesopharm Therapeutics
Stanford University Invention #4
Ka Yam Chak
kchak@stanford.edu

Picture
Entering the Start-up phase of the Breast Cancer Startup Challenge (http://breastcancerstartupchallenge.com), Mesopharm Therapeutics officially launches on April 7th, 2014.  Our goal is to revolutionize cancer therapies by combining state of the art therapeutics and theranostics.  Our talented team brings together people with diverse expertise and backgrounds from Stanford University (USA), University of Auckland (New Zealand), and University Medical Center Utrecht (Netherlands), reflecting the power of multidisciplinary and global collaboration.

OUR MISSION:

Breast Cancer is the most common cause of death in women (521 000 deaths in 2012), affecting 6.3 million people worldwide. WHO recently reported that breast cancer incidence has increased by more than 20%, while mortality has increased by 14% (Source:WHO) and called for immediate attention to address this sharp increase.

At Mesopharm, we envision to develop first-in-class biological therapies at a pre-clinical stage and accelerate their transition into the clinic. Our flagship drug candidates target specific transmembrane protein that is highly expressed in breast cancer and other tumors.  We plan to extend our therapies beyond breast cancer to other devastating cancers where our drug candidates show indication for therapeutic use. 

KEY ACTIVITIES:

  • Mesopharm launches on April 7th, 2014!!!!
  • At the full gear on drafting business plan for submitting licensing application on April 15th, 2014.  
  • Initiated engagement with the National Cancer Institute and Dr. Mitchell Ho (the inventor of the technology) to develop a CRADA (Collaborative Research and Development Agreement).  
  • Have successfully secured full support of chemistry expertise on therapeutic drug development from the Auckland Cancer Society Research Centre.   
  • Arranged a series of meetings to seed funders and seasoned entrepreneurs.  


Our Team
Picture
1 Comment
Kylie Y link
12/25/2020 02:25:36 pm

Very nice bblog you have here

Reply



Leave a Reply.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    November 2014
    August 2014
    July 2014
    April 2014
    February 2014
    January 2014

    Categories

    All
    Breast Cancer
    Breast Cancer Startup Challenge
    Duke
    Invention 3
    Invention 4
    Startup
    Tulane

    RSS Feed

The Center for Advancing Innovation, INC 2013